Effector and target modules together form a novel platform which allows us to engage target cells (e.g. tumor cells, virus infected cells) directly with
immune effector cells.
Innate
immune effector cells, including natural killer cells, macrophages, and dendritic cells, have been shown to interact with cancers and inhibit their progression.
Not exact matches
These are receptors on
immune cells, which control for example
effector T -
cells by dampening their activation if damage to healthy
cells is imminent.
In reaction to infection or inflammation,
immune system
cells known as
effector T
cells (Teffs) undergo rapid changes - arming themselves and diversifying into groups that target specific diseased
cells.
The researchers studied two types of
cells called
effector T
cells, which activate the
immune system to defend our body against different pathogens, and regulatory T
cells, which help control the
immune system and prevent it from attacking healthy parts of its environment.
However, it is this small proportion of virus that hides in the
effector memory T -
cells and stops the
immune system from fully destroying the virus and eliminating it from the body.
They systematically deleted genes for secreted
effector proteins — molecules that the parasite injects into a host
cell to modulate the
immune system during infection — and injected the altered parasites into mice with aggressive ovarian cancer.
In many cases the damage is caused by a particular group of
immune cells called
effector memory T -
cells.
Effector T
cells incite GvHD when they become overactive as the patient's
immune system starts to rebuild itself from the donor stem
cells.
The «kick - and - kill» paradigm is aimed at combining latency reversing agents (LRA) with
immune effectors, such as T -
cells, to wake up the virus and kill the reactivated
cells.
This «friendly fire» goes unchecked due to the failing of another type of
immune cell: called the T - reg, which controls T -
effector cells, shutting them down when they are not needed.
Our experts in mucosal vaccine delivery have established in vitro and in vivo models to assess the activity of adjuvants and vaccine formulations on innate and adaptive
immune cells, as well their capacity to stimulate different
effector mechanisms of clearance.
The HZI will develop a vaccination protocol for mucosal administration based on three novel strategies: (i) development and optimization of a vaccination protocol in which parenterally - primed T and B
cells are subsequently pulled into the mucosa by the local delivery of the cognate antigen to the requested
effector site, (ii) testing the co-administration of antigens with novel mucosal adjuvants using different mucosal immunisation routes and schedules, and (iii) testing various nanoparticles co-administered with different immunomodulators for their ability to generate both systemic and mucosal
immune responses following transcutaneous / trans - follicular vaccination.
Therefore, in both mice and non-human primates, HO - 1 inducers delivered locally inhibited
effector T -
cells in an antigen - specific manner, paving the way for repositioning these drugs for the treatment of
immune - mediated diseases.
Apoptosis has been implicated as a T
cell - dependent
immune effector mechanism in various forms of organ graft rejection (29 — 31).
Of special interest were ICOS, whose «role in
effector T
cell responses and anti-tumor
immune responses is now well established,» and CD40, which is «important for the maturation of antigen - presenting
cells and for enabling T
cell co-stimulation.»
Binding of adenosine to the A2A receptor on
immune cells blocks the activation and
effector functions of anti-tumor
immune cells and promotes a regulatory,
immune - suppressive phenotype.
She is registred to the National Order of Biologists in the province of Palermo; collaboration in research project from 2012 to 2015 at the Department of Biopathology and Biotechnology, University of Palermo, focusing the study on the identification of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello» of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms of the differentiation and the activation of human gammadelta T
cells as
effector cells of the
immune response against cancer and infectious diseases; she investigates about the identification and development of biomarkers of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.
Tryptophan depletion results in the inhibition of
effector T
cells and kynurenine accumulation results in the expansion of
immune - suppressant regulatory T
cells.
The adenosine A ₂ ₐ receptor is the main adenosine receptor expressed on
immune cell subsets including T -
cells, NK
cells and dendritic
cells and binding of adenosine to the A ₂ ₐ receptor on
immune cells blocks the activation and
effector functions of anti-tumor
immune cells and promotes a regulatory,
immune - suppressive phenotype.
Priority will be given to studies that evaluate combinations of agents that induce
immune deviation and / or regulation, produce
effector cell depletion or exhaustion, to achieve durable clinical remission of disease.
Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the
immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast
cells as
effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast
cells, the allergic
effector unit, mast
cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast
cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels
Whereas when an
effector is detected inside the plant
cell, the plant knows for sure it is being attacked and it activates ETI, a very strong
immune response,» said co-author Greg Martin, the Boyce Schulze Downey Professor at BTI.
Background: Many pathogens secrete
effector molecules to subvert host
immune responses, to acquire nutrients, and / or to prepare host
cells for invasion.
Because the same pool of naïve T
cells can differentiate into inflammatory
effector T
cells or inhibitory Tregs, generation of
immune responses requires promoting the differentiation of inflammatory T
cells while reciprocally inhibiting the formation of Tregs.
Besides their well - known function as
effector cells in allergic responses, mast
cells were reported to play a critical role in innate immunity and to exert important stimulatory but also suppressive functions in adaptive
immune responses.